Major improvements in stocks, including CSL Ltd (ASX: CSL), Ramsay Healthcare Ltd (ASX: RHC), and Cochlear Ltd (ASX: COH) bolstered the sector, following weakness earlier in the year.

Where does the broker see good value now?

Bell Potter has selected seven ASX healthcare shares as its key picks going forward, some of which it says could more than double in value.

One of these is Clarity Pharmaceuticals Ltd (ASX: CU6), which Bell Potter said could have some big news shortly.

The broker said:

For companies with significant clinical readouts over the near-term, it's hard to go past CU6 which is expected to deliver topline data from its two PSMA imaging Phase 3 trials in early CY27. The data from these studies should support a New Drug Application for 64Cu SAR bis PSMA in CY27. Once approved, we expect 64Cu SAR bisPSMA will enter the ~US$3b PSMA imaging market with a highly differentiated label claim to the incumbents.

Bell Potter has a speculative buy rating on the shares with a $6.40 price target.

The broker is also predicting solid share price gains for Mesoblast Ltd (ASX: MSB), which has been preforming well since gaining FDA approval for its drug Ryoncil in late 2024.

Bell Potter said Mesoblast was also progressing a lower back pain drug, with a large potential market.

Its price target for Mesoblast is $4.45.

Other companies which are scaling up in the US are Lumos Diagnostic Holdings Ltd (ASX: LDX) and Aroa Biosurgery Ltd (ASX: ARX).

Bell Potter said regarding these two:

LDX is rapidly scaling its commercial channels ahead of its first flu season in North America, while ARX is driving strong direct growth through Myriad and positioning to capitalise on disruption across the outpatient chronic wound market with Symphony. Both remain well positioned in sizeable US growth opportunities.

Bell Potter has a price target of 25 cents on Lumos and $1.09 on Aroa.

The broker also likes Vitrafy Life Sciences Ltd (ASX: VFY), which it said "has recently emerged with the potential to develop dominant positions across various large cryopreservation markets, but particularly in the blood products segment''.

Bell Potter has a price target of $5.15 on Vitrafy.

The broker said Cogstate Ltd (ASX: CGS) delivered "stellar returns" in FY26, "following significant contract wins across an increasingly diverse range of clinical indications and channel partners''.

It has a price target of $3.70 on Cogstate.

And lastly, Bell Potter is also bullish on Pro Medicus Ltd (ASX: PME), which it said "continues to win ever more business in the US''.

Bell Potter has a price target of $226 on Pro Medicus.

The post 7 ASX healthcare stock picks from Bell Potter appeared first on The Motley Fool Australia.

Year to date, it has risen almost 190%. 

A new report from Bell Potter indicates there is plenty more growth to come as this ASX healthcare stock looks to address a crisis that could help it become a major Australian healthcare success story.

Company overview

Vitrafy Life Sciences was founded in November 2017 with a mission to become a global leader in cryopreservation by significantly improving cell survival of biological materials. 

Vitrafy has designed and developed an innovative solution for the advancement of cryopreservation. 

One of these devices is Lifechain – an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials.

FY26 result highlights

This ASX healthcare company released full-year results yesterday.

The company reported a FY26 net loss of $16.2 million, which was slightly better than what Bell Potter expected and an improvement on last year.

The company spent more cash during the year as it invested heavily in building its US operations, regulatory approvals, and commercial activities.

After raising $30 million, it finished the year with $41.2 million in cash, although it will likely need more funding before it becomes profitable.

Major turning point 

According to yesterday's report, Bell Potter believes this ASX healthcare stock is nearing a major turning point. 

A successful US military platelet study has generated interest from the civilian healthcare market, while problems with the US blood supply system have created a significant opportunity for the Guardion technology as it approaches FDA approval. 

The broker also sees potential in cell and gene therapy, with the first revenue-generating contract possible in the first half of FY27, and in animal reproduction, where a joint commercial launch could occur within the next 6 to 9 months. 

Upside intact 

Bell Potter has maintained its speculative buy rating and $5.15 price target, believing commercial revenue could begin in FY27 across all three target markets. 

The broker said if the company secures FDA approval and signs its first commercial contracts, the company could generate significant shareholder value and benefit from what it sees as a transformational opportunity in the US blood sector.

From current levels, the price target from Bell Potter indicates an upside potential of approximately 40%. 

We consider the US blood sector crisis may become transformational for VFY, building into an Aussie champion.

The post Why this ASX healthcare stock is at the cusp of a 'Transformational Opportunity' – Expert appeared first on The Motley Fool Australia.

The company has designed and developed an innovative solution to advance cryopreservation, including smart devices, a quality management software platform, and smart packaging solutions.

Commercial success has led to significant share price gains of almost 150% in 2026 alone. 

A new report from Bell Potter suggests this is likely to continue, with the broker significantly increasing its 12-month price target. 

$30 million capital raise

Vitrafy recently raised $30 million from institutional investors at $2.60 per share.

Following this, the company announced a Share Purchase Plan (SPP). 

The company said the SPP intends to raise up to $2 million. 

The SPP provides Eligible Shareholders with the opportunity to acquire new fully paid ordinary shares in the Company ("New Shares") at the same price as the institutional placement announced to the ASX on Friday, 12 June 2026, which raised A$30 million.

Each Eligible Shareholder may apply for up to A$30,000 worth of New Shares at the offer price of A$2.60 per New Share, irrespective of the size of their holding in Vitrafy, without incurring brokerage or transaction costs.

What is Bell Potter's view?

Following this announcement, the team at Bell Potter provided updated guidance on this ASX healthcare stock. 

The broker largely appears constructive/bullish on the capital raise, viewing it as growth funding rather than a rescue financing.

According to the report, commercial traction is improving, with positive developments in military blood studies, animal reproduction partnerships, and growing interest from the U.S. civilian blood market.

The $32 million total raise (A$30m placement + A$2m SPP) provides enough capital to manufacture approximately 100 units and accelerate commercial deployment. 

Bell Potter estimates those units could generate around A$12 million of annual managed-service revenue, plus recurring consumable sales.

Target price increase for ASX healthcare stock

This ASX healthcare stock closed trading yesterday at $3.19 per share. 

The team at Bell Potter have now upgraded their 12-month price target to $5.15 (previously $3.00). 

It has retained its speculative buy recommendation. 

This indicates an upside potential of 61% from current levels. 

The capital raising and developments in the Red Blood Cell market have instigated a revision to our estimates, particularly from FY28 on the revenue line, where we see 175 total units being installed by FY30 which could generate $80m in annual revenue.

We still anticipate VFY reaching breakeven by FY30.

The post This ASX healthcare stock just got a big upgrade following capital raise appeared first on The Motley Fool Australia.

The company has now seen its share price rise almost 200% year to date. 

Company overview

Vitrafy is a biotechnology company focused on improving cryopreservation, which is the process of freezing and storing biological materials such as cells, tissues, reproductive material, and potentially other medical or veterinary products.

The company has developed its own Vitrafy Cryopreservation Technology (VCT), which combines:

• Smart freezing and thawing devices
• Quality management software
• Specialised packaging solutions

The goal of VCT is to better control temperature changes during freezing and thawing. This helps more cells survive and remain functional after they are thawed.

According to Vitrafy's testing and independent validation studies, its technology has produced higher cell survival rates and better cell quality than many existing industry methods and standards.

Why is it hitting new highs?

There was no price-sensitive news out of this healthcare stock on Tuesday. 

However, last week, the company announced a partnership with Vitalant Innovation Center ("Vitalant") to configure Vitrafy's next-generation cryopreservation ecosystem to solve the looming crisis for red blood cell preservation. 

The partnership aims to address a pivotal industry transition: as existing frozen red blood cell ("RBC") technologies reach the end of their operational life, with no replacement presently available.

Speaking on the partnership, Managing Director and CEO, Brent Owens, commented:

We are really excited to partner with Vitalant to actively address an issue of national significance with one of the leading blood market participants in the USA. 

The recognition of Vitrafy's cryopreservation ecosystem as the next generation solution to this crisis reinforces our belief that we are securing meaningful market traction and creating a pathway to significant commercial scale. 

We see this partnership as the first of several potential civilian blood opportunities that have stemmed from the successful results in the U.S Army platelets study.

This new partnership, along with recent contract wins, has likely propelled the healthcare stock to new all-time highs. 

Can this healthcare stock keep rising?

This ASX healthcare stock is now at a new 52-week high following Tuesday's gain. 

Holders of the stock may now be considering profit-taking, while prospective investors will be considering the future potential of this growth stock.

Earlier this year, Bell Potter placed a price target of $3.00 on this healthcare stock. 

Meanwhile, Morgans is optimistic about the company following recent contract wins. 

Despite the positive views, it is now trading above broker targets. 

However, it's worth noting that growth stocks can remain attractive investments even when trading above broker price targets. 

Rapid earnings and revenue growth can cause a company's intrinsic value and share price to increase faster than analysts can update their forecasts and rerate the stock.

The post Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday? appeared first on The Motley Fool Australia.

Vitrafy researches and develops cryopreservation technology. The company offers cryopreservation devices, thawing devices, packaging, and software platform.

In 2026, it has risen an impressive 107%. 

This included a 13% jump last Friday after the company released an announcement to the ASX. 

What did the company announce?

On Friday, the healthcare company announced the successful completion of the Phase II in-vitro study with United States Army Institute of Surgical Research (part of the Defense Health Agency) ("USAISR"). 

According to the release, excellent results were achieved using the Vitrafy cryopreservation ecosystem across all tested protocols when compared to existing regulatory and quality guidelines for platelet use.

Building upon the Phase I results, the Phase II USAISR in-vitro results highlight that all protocols tested via Vitrafy's cryopreservation ecosystem outperform the existing regulatory and quality guidelines currently set for the use of platelets

What does this all mean?

The company tested different ways of freezing and thawing platelets (blood components used to stop bleeding).

All methods passed the minimum medical standards needed for human use.

One method in particular – using 3% DMSO without needing a "wash" step – performed best.

Normally frozen platelets are difficult and expensive to prepare after thawing.

Vitrafy's "no-wash" process means hospitals, ambulances, military units, or remote clinics could potentially thaw and use platelets quickly without special lab equipment or trained technicians.

That could make it easier to store emergency blood supplies for disasters, trauma care, rural medicine, and battlefield injuries.

They achieved 94% platelet recovery after thawing, which means most platelets survived the freezing process and still functioned properly.

They also maintained strong clotting ability, which is critical in trauma situations.

Investors were seemingly pleased with these results, as the ASX healthcare stock rose 13% last Friday following the release. 

What is Morgan's take?

Following this announcement, the team at Morgans provided updated guidance on this ASX healthcare stock. 

It said Vitrafy has released final Phase II in-vitro platelet results from USAISR, with all three cryopreservation protocols exceeding fresh-platelet quality benchmarks. 

The headline result was 94% post-thaw recovery using the 3% DMSO no-wash protocol, well ahead of the FDA/AABB (~75%) and European (~50%) thresholds. The study is independently authored by the US Army across 20 donors and 60+ samples at commercial volumes, delivering on a core IPO commitment made at listing in November 2024. 

No FDA-approved no-wash frozen platelet product exists commercially in the US, positioning Vitrafy to address a genuine category gap. Shares trading up strongly from the $1.20 YTD lows, and +27% on the 2024 IPO price.

This ASX healthcare stock closed trading last week at $2.65. 

Current targets from brokers are hovering around the $3.00 mark. 

The post What is Morgan's updated view on this red hot ASX healthcare stock? appeared first on The Motley Fool Australia.

During this time, the ASX stock has risen over 60%.

But if you thought you were late to the party, think again.

That's because Bell Potter believes the life sciences company's shares could continue to rise over the next 12 months.

What is this ASX stock?

Vitrafy is aiming to become a global leader in cryopreservation by significantly improving cell survival of biological materials.

The ASX stock has designed and developed an innovative solution for the advancement of cryopreservation which includes smart devices, a quality management software platform, and smart packaging solutions.

Bell Potter highlights that after 18 months as a listed company, Vitrafy is approaching an inflection point. It said:

It has been c.18 months since the IPO and VFY are now approaching the point where commercial revenues are within reach. The final report on the Phase II USAISR study is due to be released in 4Q26, with an understanding that the study has been successful and passed regulatory standards.

An update on commercial activity with USAISR is expected in 1H27. The market would be hoping for a final commercial agreement. This collaboration is understood to have created material inbound interest from the civilian blood products sector and follows a recent end-of-life announcement for a legacy technology. No details were provided but this event could be a catalyst for demand for VFY's liquid nitrogen free cryopreservation technology.

Big potential returns

According to the note, Bell Potter has retained its speculative buy rating on the ASX stock with a significantly improved price target of $3.00 (from $2.25).

Based on its current share price of $2.10, this implies potential upside of 42% for investors over the next 12 months.

While Bell Potter still has a speculative rating on the stock, it notes that it has removed a 10% risk rating in response to operational progress. It concludes:

We judge the progress VFY has made in blood products and animal production to be sufficient to remove the 10% risk rating we had applied to our revenue forecasts, lifting our FY27e/FY28e revenue estimates by c.11%. Subsequently, this lifts our DCF valuation by c.33% to $3.00/sh.

Since the post IPO low of $1.08 a year ago, VFY's share price has effectively doubled as confidence toward commercialisation has increased. Key catalysts relate to 1) securing commercial arrangements with USAISR and 2) FDA registration for the Guardion cryopreservation device.

The post Up 60%: Why this exciting ASX stock could keep rising appeared first on The Motley Fool Australia.

At the time of writing: 

• Elevra Lithium Ltd (ASX: ELV) is up 7% to fresh highs of $13.80
• SKS Technologies Group Ltd (ASX: SKS) is up 1.6% to $7.20
• Vitrafy Life Sciences Ltd (ASX: VFY) is up 10% to $2.19

These ASX shares are now hitting fresh yearly highs. Many investors might now be questioning if it's too late to gain positions in these companies. 

Let's see what analysts are projecting. 

Elevra Lithium

Elevra Lithium engages in the exploration, development, and mining of lithium raw materials. Its portfolio includes projects in Québec, Canada, the United States, Ghana, and Western Australia. 

It has been one of the many ASX lithium shares charging higher this year. 

A key catalyst has been the global oil shock linked to the Iran conflict, which has increased interest in electric vehicles (EVs) as an alternative to expensive fossil fuels. This shift is boosting expected demand for lithium, a critical battery material.

At the time of writing, this ASX lithium stock is up 72% year to date. 

However, experts are suggesting that there is limited further upside. 

The average analyst forecast via TradingView indicates a fair price target of $14.03. 

This is just 2% higher than today's share price. 

SKS Technologies

SKS Technologies engages in the development and distribution of technology products. It provides audiovisual products & solutions and electrical and communications cabling for the commercial, retail, health, defence, and education markets.

It has been drawing positive outlooks from brokers thanks to its exposure to the booming data centre (DC) market.

At the time of writing, it is up 81% year to date and sits at $7.18 per share. 

This is significantly above recent price targets from Morgans, which recently retained its accumulate rating on its shares with a revised price target of $6.70.

Other analysts' ratings are hovering around $6.47 per share, which is 9.8% below current levels. 

Vitrafy Life Sciences

Vitrafy Life Sciences developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials.

At the time of writing, its share price is up 71% year to date. 

Unlike the previous two ASX shares mentioned above, VFY shares may still have modest upside. 

According to analyst ratings via TradingView, VFY could rise a further 6% from current levels. 

The post What are brokers saying about these ASX shares hitting 52-week highs appeared first on The Motley Fool Australia.

Its share price fell almost 2% yesterday. 

For context, the S&P/ASX 200 Index (ASX: XJO) gained nearly 1%. 

Vitrafy Life Sciences develops a range of proprietary smart cryopreservation hardware devices along with Lifechain – an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials.

The company released FY26 Half Year Results that included: 

• Underlying Operating Loss of.-$7.5m
• Operating Cash Outflow of $6.6m v -$4.0m PcP. 
• Cash and cash equivalents ended the period at $22.8m v $29.5m at FY25

Despite yesterday's dip, the share price remains up more than 26% year to date. 

Following its earnings results, the team at Bell Potter released updated guidance on this ASX healthcare stock. 

Here is what the broker had to say. 

Commercial visibility 

Bell Potter acknowledged in its report that currently, most of this ASX healthcare stock's income comes from government R&D incentives and grants, not from selling products.

However, this is expected to change over time as the company starts selling its technology commercially.

Importantly, it has signed its first major commercial agreement with IMV Technologies.

This deal is important because it validates Vitrafy Life Sciences' technology and could lead to very large future revenue (over US$100m per year if widely adopted).

It's important for prospective investors to be aware there is still risk, because the agreement needs to be expanded into a long-term deal.

If the partnership succeeds, it could be a turning point for the company.

Execution risk remains in moving to the long-term agreement, but assuming the partnership is consummated, the IMV partnership may prove to be the game changer the market is seeking. We assume a c.12% penetration across bovine / porcine segments (FY30e).

Upside remains in tact 

Bell Potter has maintained its speculative buy recommendation for this ASX healthcare stock. 

The broker has a price target of $2.25 on Vitrafy Life Sciences. 

From yesterday's closing price of $1.62, this indicates an upside of 38.89%. 

Bell Potter said beyond the IMV partnership, this ASX healthcare stocks' share price could be boosted by positive results from its Phase 2 US military trial, FDA approval of its Guardion medical device, and progress in commercialising its cryopreservation technology for Cell & Gene Therapy.

These events would signal that the technology is working, approved, and starting to generate real commercial interest.

The post Why this ASX healthcare stock is a speculative buy appeared first on The Motley Fool Australia.

It is an Australian innovator in cryopreservation solutions. 

It develops a range of proprietary smart cryopreservation hardware devices along with Lifechain – an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. 

This ASX healthcare stock lost more than 5% in yesterday's trading after the company released its quarterly activities report.

However a new report from broker Bell Potter suggests it could be an undervalued ASX healthcare stock with plenty of upside. 

2Q26 Result

In yesterday's report, the company released financial information. 

It reported improved operating cash flow in 2Q26 with a net outflow of approximately $2.9m.

This was down from roughly $3.7m in 1Q26.

Cash costs increased 47% YoY to $5.0m.

The improvement in cash flows reflected the receipt of $1.8m in grant funding as part of a $4.8m Industry Growth Program grant to commercialise cryopreservation technology.

The $10m the Company had on term deposit rolled over during the quarter.

Across the balance of FY26, average quarterly cash costs are expected to increase around 10-15% in the current half, coinciding with the Company's investment in the ramp up of key regulatory testing work for medical device registration, expansion of the commercial team in the US and investment in an initial fleet of devices to meet anticipated demand.

Investors largely rotated out of the stock based on this report, as this ASX healthcare stock fell 5.66% on Thursday.

Opportunity knocks for this ASX healthcare stock

After yesterday's stock price fall, new analysis from Bell Potter indicates the stock could be significantly undervalued.

The broker said the strategic collaboration with global animal reproduction leader IMV Technologies (over 500m inseminations annually) opens a potential $100m+ managed services opportunity at full penetration across IMV's ~1,200 collection centres. 

The 12-month co-development agreement is expected to deliver ~$0.93m in revenue through CY26 and positions VFY for a longer-term partnership while accelerating animal market progress and allowing greater focus on the North American human health market.

The maiden commercial agreement with IMV appears quite prospective and marks the beginning of commercial visibility into VFY's future.

The broker has a speculative buy rating on this ASX healthcare stock. 

It also upgraded its price target to $2.28 (previously $2.10). 

From yesterday's closing price, this indicates an upside of 30.29%. 

The post This broker just upgraded this ASX healthcare stock and is predicting 30% upside appeared first on The Motley Fool Australia.